Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 3/20 | 1.00 |
| ▸ | CA3 | P07451 | 3/20 | 1.00 |
| ▸ | CA4 | P22748 | 3/20 | 1.00 |
| ▸ | CA6 | P23280 | 3/20 | 1.00 |
| ▸ | CA5A | P35218 | 3/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 1.00 |
| ▸ | CA9 | Q16790 | 3/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | TTR | P02766 | 2/20 | 1.00 |
| ▸ | APP | P05067 | 2/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 2/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 2/20 | 1.00 |
| ▸ | DPP4 | P27487 | 2/20 | 1.00 |
| ▸ | MMP1 | P03956 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caffeic Acid SCHEMBL23359 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL23358 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL29447135 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL30501140 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL7064846 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL30050844 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL1262229 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL29353048 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL21114743 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CA12CA1CA2 | |
| Caffeic Acid SCHEMBL9308249 | 0.98 | KDM4E (0.96) | KDM4EHSD17B10CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2969029-A2 | USE OF COSMETICALLY OR DERMATOLOGICALLY SAFE SUBSTITUTED MICHAEL ACCEPTORS FOR THE PREVENTION, REDUCTION OR PROPHYLAXIS OF THE TYROSINASE ACTIVITY OF THE HUMAN SKIN AND/OR THE LIGHTENING OF THE HUMAN SKIN | Beiersdorf AG (DE) | 2016-01-20 | — | — | EP | claimed |
| CN-105050663-A | Use of cosmetically and dermatologically safe substituted michael acceptors to prevent, reduce or prevent human skin tyrosinase activity and/or to lighten skin | BEIERSDORF AG | 2015-11-11 | — | — | CN | claimed |
| WO-2014139756-A2 | USE OF COSMETICALLY OR DERMATOLOGICALLY SAFE SUBSTITUTED MICHAEL ACCEPTORS FOR THE PREVENTION, REDUCTION OR PROPHYLAXIS OF THE TYROSINASE ACTIVITY OF THE HUMAN SKIN AND/OR THE LIGHTENING OF THE HUMAN SKIN | BEIERSDORF AG (DE) | 2014-09-18 | — | — | WO | claimed |
| CN-103257201-A | Method for simultaneous determination of caffeic acid and 8 flavonoids in propolis by using high performance liquid chromatography | HANGZHOU BEEWORDS BEE INDUSTRY CO LTD | 2013-08-21 | — | — | CN | claimed |
| CN-122080255-A | Chitosan-organic acid supermolecule ionic salt and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122038069-A | Natural sweet wine low-sulfur brewing method for harvesting white grape after delaying red turning | 宁夏大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260048071-A1 | 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS | Cadrenal Therapeutics, Inc. | 2026-02-19 | — | — | US | disclosed |
| EP-4615432-A2 | 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS | Veralox Therapeutics Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| CN-120189402-A | A preparation comprising 2 Chinese medicinal materials for treating nonalcoholic fatty liver disease | 上海中医药大学附属曙光医院 | 2025-06-24 | — | — | CN | disclosed |
| CN-116298001-B | Vitex negundo particle and detection method and application of fingerprint thereof | 上海上药杏灵科技药业股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-103257201-A | Method for simultaneous determination of caffeic acid and 8 flavonoids in propolis by using high performance liquid chromatography | HANGZHOU BEEWORDS BEE INDUSTRY CO LTD | 2013-08-21 | — | — | CN | disclosed |
| US-20100203175-A1 | DEGLYCATION OF AGEs | BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S. (FR) | 2010-08-12 | — | — | US | disclosed |
| CN-101765432-A | AGE deglycation | BASF BEAUTY CARE SOLUTIONS F | 2010-06-30 | — | — | CN | disclosed |
| US-20090092975-A1 | SELECTABLE MARKER | MOLOGIC LTD (GB) | 2009-04-09 | — | — | US | disclosed |
| US-20070042026-A1 | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions | MORNINGSIDE VENTURE INVESTMENTS LIMITED | 2007-02-22 | — | — | US | disclosed |
| EP-0975224-A1 | PROCESS AND COMPOSITIONS FOR ENHANCING RELIABILITY OF EXOGENOUS CHEMICAL SUBSTANCES APPLIED TO PLANTS | MONSANTO COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| US-6020287-A | USING MIXTURE OF HERBICIDE AND PHENYL-SUBSTITUTED OLEFIN COMPOUND | MONSANTO COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1998033385-A1 | PROCESS AND COMPOSITIONS FOR ENHANCING RELIABILITY OF EXOGENOUS CHEMICAL SUBSTANCES APPLIED TO PLANTS | MONSANTO COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092975-A1 | SELECTABLE MARKER | AMD1, PADI1, PSAT1 | KDM4E 3611/4885HSD17B10 193/4885CA12 1162/4885 |
| US-20260048071-A1 | 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS | ALOX12, ALOX5, ALOX15 | KDM4E 1329/4885HSD17B10 945/4885CA12 3274/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | KDM4E 2468/4885HSD17B10 1517/4885CA12 1005/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | KDM4E 3824/4885HSD17B10 3242/4885CA12 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.